Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.26 USD | -2.27% | +11.39% | -14.18% |
06-25 | Arrowhead Pharmaceuticals to Advance Investigational Medicine Plozasiran Into Late-stage Cardiovascular Study | MT |
06-25 | Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.18% | 3.34B | |
+16.49% | 122B | |
+21.73% | 116B | |
+22.18% | 27.03B | |
-21.81% | 20.36B | |
-16.89% | 16.43B | |
-18.81% | 15.91B | |
-44.74% | 15.6B | |
+62.72% | 14.94B | |
+3.09% | 13.59B |
- Stock Market
- Equities
- ARWR Stock
- News Arrowhead Pharmaceuticals, Inc.
- Transcript : Arrowhead Pharmaceuticals, Inc., Q1 2023 Earnings Call, Feb 06, 2023